Mosunetuzumab
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells) . Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) [1][2].
Product Specifications
CAS Number
1905409-39-3
Product Name Alternative
BTCT-4465A; RG-7828; RO7030816
UNSPSC
12352203
Target
CD20; CD3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/mosunetuzumab.html
Purity
99.05
Solubility
H2O
Smiles
[Mosunetuzumab]
Molecular Weight
(144 kDa)
References & Citations
[1]Lihua E Budde, et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol. 2022 Feb 10;40 (5) :481-491.|[2]Gregory Z Ferl, et al. A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clin Transl Sci. 2018 May;11 (3) :296-304.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
HA723471 100 µL
Human Nectin-4 Recombinant Rabbit monoclonal Antibody
Sign In for Pricing
View Details 
